These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3818941)

  • 1. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters.
    Moody DJ; Kagan J; Liao D; Ellison GW; Myers LW
    J Neuroimmunol; 1987 Mar; 14(2):161-73. PubMed ID: 3818941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment.
    Moody DJ; Fahey JL; Grable E; Ellison GW; Myers LW
    J Neuroimmunol; 1987 Mar; 14(2):175-82. PubMed ID: 2950131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial.
    Myers LW; Fahey JL; Moody DJ; Mickey MR; Frane MV; Ellison GW
    Arch Neurol; 1987 Aug; 44(8):828-32. PubMed ID: 2957983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.
    Shih WW; Baumhefner RW; Tourtellotte WW; Haskell CM; Korn EL; Fahey JL
    Clin Exp Immunol; 1983 Jul; 53(1):122-32. PubMed ID: 6603303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: studies in patients with chronic progressive multiple sclerosis.
    Chiappelli F; Myers LW; Ellison GW; Liao D; Fahey JL
    Int J Immunopharmacol; 1991; 13(5):455-61. PubMed ID: 1783458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression.
    Martínez-Maza O; Moody DJ; Rezai AR; Ellison GW; Myers LW; Tourtellotte WW; Fahey JL
    J Clin Immunol; 1987 Mar; 7(2):107-13. PubMed ID: 3571433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis.
    Brinkman CJ; Nillesen WM; Hommes OR
    Acta Neurol Scand; 1984 Feb; 69(2):90-6. PubMed ID: 6231801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of clinical and immunologic states in multiple sclerosis.
    Mickey MR; Ellison GW; Fahey JL; Moody DJ; Myers LW
    Arch Neurol; 1987 Apr; 44(4):371-5. PubMed ID: 2950845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
    Berd D; Mastrangelo MJ
    Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
    Gonsette RE; Defalque A; Demonty L
    Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
    Rinaldi L; Perini P; Calabrese M; Gallo P
    Neurol Sci; 2009 Oct; 30 Suppl 2():S171-3. PubMed ID: 19882369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid.
    Uitdehaag BM; Nillesen WM; Hommes OR
    Acta Neurol Scand; 1989 Jan; 79(1):12-7. PubMed ID: 2784607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis.
    Hafler DA; Orav J; Gertz R; Stazzone L; Weiner HL
    J Neuroimmunol; 1991 May; 32(2):149-58. PubMed ID: 1672870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
    Comabella M; Balashov K; Issazadeh S; Smith D; Weiner HL; Khoury SJ
    J Clin Invest; 1998 Aug; 102(4):671-8. PubMed ID: 9710434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
    Smith DR; Balashov KE; Hafler DA; Khoury SJ; Weiner HL
    Ann Neurol; 1997 Sep; 42(3):313-8. PubMed ID: 9307252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients.
    Salmaggi A; Milanese C; Eoli M; La Mantia L; Nespolo A; Dufour A
    Int J Neurosci; 1994 Jun; 76(3-4):305-12. PubMed ID: 7960486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
    Weiner HL; Mackin GA; Orav EJ; Hafler DA; Dawson DM; LaPierre Y; Herndon R; Lehrich JR; Hauser SL; Turel A
    Neurology; 1993 May; 43(5):910-8. PubMed ID: 8388090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset.
    Berd D; Mastrangelo MJ
    Cancer Res; 1987 Jun; 47(12):3317-21. PubMed ID: 2953413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.